Posted by Michael Wonder on 02 May 2016
Post-market reviews of pulmonary arterial hypertension medicines and biological DMARDs to treat severe chronic plaque psoriasis
2 May 2016 - The public consultation process is now open for two PBAC post-market reviews.
The reviews will be conducted on:
- Medicines used to treat patients with pulmonary arterial hypertension (PAH)
- biological disease modifying anti-rheumatic drugs (bDMARDs) used to treat patients with severe chronic plaque psoriasis
Submissions will be accepted from 2 May 2016 until 5pm on 16 May 2016, in line with the post-market review framework.
